BA
Bajaj Finserv Healthcare Fund Direct Growth
Latest NAV
+20.97% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
0.90%
AUM
₹406 Cr
Min SIP
₹500
Min lump sum
₹500
1Y
+20.97%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Dec 2024
Where the NAV sits & how risky it is
₹11.73
52-week range
at 79%
₹11.73
Low 23 Mar 2026₹9.15
High 08 Sep 2026₹12.43
Risk level
Very High
Low
Very high
NAV history
30 Dec 2024
Since inception
01 Oct 2026
Returns by period
1W
-3.73%
1M
-4.25%
3M
+5.68%
6M
+26.13%
1Y
+20.97%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹500
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 95.79%
Cash & other 4.21%
Sector split
Country split
Top 5 hold 35.0%
Top 10 hold 57.0%
36 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
9.07%
|
+5.55% |
| 2 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
6.73%
|
+20.66% |
| 3 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.54%
|
+9.26% |
| 4 | Piramal Pharma
INE0DK501011 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.51%
|
-1.93% |
| 5 | Aurobindo Pharma
INE406A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.17%
|
+29.69% |
| 6 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.26%
|
+18.24% |
| 7 | Rubicon Research
INE506V01022 |
Healthcare Drug Manufacturers - General |
India |
4.52%
|
+103.94% |
| 8 | Neuland Laboratories
INE794A01010 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.39%
|
+19.29% |
| 9 | Emcure Pharmaceuticals
INE168P01015 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.18%
|
+33.13% |
| 10 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
3.68%
|
+3.15% |
About this scheme
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
Fund manager(s): Siddharth Chaudhary, Sorbh Gupta, Bharat Hegde
Exit load: 1% for redemption within 3 Months
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
27 Dec 2024
Lump-sum min
₹500
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 100.6 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 12.4 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 9.6 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 9.6 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 8.3 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 8.2 pts ahead of this fund